The Latest Cardiac and Vascular News
Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership.
July 25, 2024 06:00 AM Eastern Daylight Time HOUSTON–(BUSINESS WIRE)–The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR’s TAH […]
MIAMI, July 25, 2024 /PRNewswire/ — AbbaDox, a leading provider of cloud-based healthcare solutions, is pleased to announce a strategic relationship with Merge Healthcare Solutions to deliver an enhanced suite of radiology workflow solutions. Merge ambulatory radiology workflow solutions…
July 25, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge […]
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024.
The studies presented this week at the Society of Neurointerventional Surgery (SNIS) underline the company’s rigorous evidence-based approach to developing and validating novel AI solutions that can help to optimize patient care across stroke networks. OXFORD, England and CHICAGO, July…
In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States.
Late-Breaking Data Presented at SNIS Suggest Lower Rates of Rescue Therapy Than Prior Thrombectomy Trials; Rapid Reperfusion Time; High Rates of Reperfusion July 24, 2024 01:30 PM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that late-breaking data from the Imperative Trial were presented at the Society of […]
